Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) has announced the appointment of Jon DiVincenzo as President and Chief Operating Officer, effective September 9, 2024, replacing Andy Last, who is retiring. Mr. DiVincenzo joins Bio-Rad from Labcorp Holdings Inc., where he held various global operational and commercial leadership roles. Bio-Rad's Chairman and Chief Executive Officer, Norman Schwartz, expressed excitement about the appointment, highlighting Mr. DiVincenzo's over thirty years of industry experience in both life science and clinical diagnostics.
In 2023, Bio-Rad reported revenues of $2.7 billion and operates with over 7,700 employees globally. The company's customer base includes universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies.
The incoming President and COO, Jon DiVincenzo, expressed his excitement in joining Bio-Rad and looks forward to working with the executive team to continue the company's progress towards achieving its long-term transformational and growth objectives.
This announcement comes as Bio-Rad continues to develop, manufacture, and market a broad range of products for the life science research and clinical diagnostics markets. The market has reacted to these announcements by moving the company's shares -1.1% to a price of $322.71. For the full picture, make sure to review Bio-Rad Laboratories's 8-K report.
